Table. Demographic characteristics and signs and symptoms for 56 case-patients who had laboratory-confirmed EHF, Bundibugyo District, Uganda, in 2007*.
| Characteristic | Case-patients confirmed by acute-phase sample, n = 43 |
Total no. confirmed case-patients, n = 56 | ||
|---|---|---|---|---|
| No. survived, n = 26 | No. died, n = 17 | p value | ||
| Mean age, y (range) | 33 (12–50) | 42(20–70) | 0.039† | 37.4 (11–70) |
| Male sex (%) | 16 (62) | 8 (47) | >0.100‡ | 30 (54) |
| Mean incubation period, d (95% CI)§ |
5.7 (4.4–7.0) |
7.4 (5.4–9.3) |
>0.100† |
6.3 (5.2–7.3) |
| Signs and symptoms, no. reporting/no. available (%)¶ | ||||
| Fever | 26/26 (100) | 16/16 (100) | >0.100 | 55/55 (100) |
| Fatigue | 22/23 (96) | 14/14 (100) | >0.100 | 49/50 (98) |
| Headache | 21/25 (84) | 14/15 (93) | >0.100 | 48/53 (91) |
| Nausea/vomiting | 24/26 (92) | 13/15 (87) | >0.100 | 48/54 (89) |
| Abdominal pain | 23/26 (88) | 13/14 (93) | >0.100 | 47/53 (89) |
| Muscle/joint pain | 19/23 (83) | 12/14 (86) | >0.100 | 44/50 (88) |
| Diarrhea | 24/26 (92) | 13/15 (87) | >0.100 | 47/54 (87) |
| Anorexia/weight loss | 19/23 (83) | 12/15 (80) | >0.100 | 43/51 (84) |
| Difficulty swallowing | 10/23 (43) | 6/15 (60) | >0.100 | 27/51 (53) |
| Rash | 9/26 (35) | 5/15 (33) | >0.100 | 25/54 (46) |
| Difficulty breathing | 6/23 (26) | 8/14 (57) | 0.085 | 23/50 (46) |
| Hiccups | 4/23 (17) | 6/15 (40) | >0.100 | 16/51 (31) |
| Bleeding# | 11/26 (42) | 9/17 (53) | >0.100 | 30/56 (54) |
*EHF, Ebola hemorrhagic fever; CI, confidence interval. †By 2-sample t-test. ‡By χ2 test. §For case-patients reporting contact with a confirmed case-patient, or contact with case-patient X (see text for full description), based on time from last reported contact with case-patient to development of signs and symptoms (n = 16 for case-patients in Survived column; n = 8 for case-patients in Died column; n = 24 for all confirmed case-patients). ¶No. case-patients reporting the sign or symptom/no. case-patients with information available about presence of that the sign or symptom. p value was determined by Fisher exact test in which a comparison was made between the proportion of case-patients who survived vs. those who died. #At least 1 of the following manifestations: bleeding from injection site, gums, eyes, nose, vagina; black or bloody stool; bloody vomitus; hematuria.